Japan's MOH In Drug Price Survey
Japan's Ministry of Health and Welfare has announced a special survey of drug prices to cover the past 12 months to September 1996, the purpose of which is to allow the Ministry to prepare a realistic budget in November.
The budget will anticipate a 2% increase in consumption tax to a new level of 5%, scheduled to take effect next April. An average price cut of 3% in the official national health care insurance yakka drug price is expected to result from the survey, and would take effect at the same time.
This is a departure from the policy in recent years of biannually surveying and adjusting the prices of drugs listed for sale under the NHI system. How the "R" (reasonable) zone, which has allowed an annually decreasing percentage for discounting of drugs, will be applied is also unclear.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze